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The Vpu accessory protein promotes HIV-1 release by counteracting Tetherin/BST-2, an 
interferon-regulated restriction factor, which retains virions at the cell-surface. Recent 
reports proposed β-TrCP-dependent proteasomal and/or endo-lysosomal degradation of 
Tetherin as potential mechanisms by which Vpu could down-regulate Tetherin cell-
surface expression and antagonize this restriction. In all of these studies, Tetherin 
degradation did not however entirely account for Vpu anti-Tetherin activity. Here, we 
show that Vpu can promote HIV-1 release without detectably affecting Tetherin steady-
state levels or turnover, suggesting that Tetherin degradation may not be necessary and/or 
sufficient for Vpu anti-Tetherin activity. Even though Vpu did not enhance Tetherin 
internalization from the plasma membrane (PM), it did significantly slow-down the 
overall transport of the protein towards the cell-surface.  Accordingly, Vpu expression 
caused a specific removal of cell-surface Tetherin and a re-localization of the residual 
pool of Tetherin in a perinuclear compartment that co-stained with the TGN marker 
TGN46 and Vpu itself. This re-localization of Tetherin was also observed with a Vpu 
mutant unable to recruit β-TrCP, suggesting that this activity is taking place 
independently from β-TrCP-mediated trafficking and/or degradation processes. We also 
show that Vpu co-immunoprecipitates with Tetherin and that this interaction involves the 
transmembrane domains of the two proteins. Importantly, this association was found to 
be critical for reducing cell-surface Tetherin expression, re-localizing the restriction 
factor in the TGN and promoting HIV-1 release. Overall, our results suggest that 
association of Vpu to Tetherin affects the outward trafficking and/or recycling of the 
2 
1 
2 
3 
4 
5 
6 
restriction factor from the TGN and as a result promotes its sequestration away from the 
PM where productive HIV-1 assembly takes place. This mechanism of antagonism that 
results in TGN trapping is likely to be augmented by β-TrCP-dependent degradation, 
underlining the need for complementary and perhaps synergistic strategies to effectively 
counteract the powerful restrictive effects of human Tetherin. 
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Restriction factors are cellular proteins that interfere with the multiplication and 
transmission of viruses and are therefore important components of natural immunity. 
Tetherin (also known as BST-2) is a recently identified restriction factor that traps viruses 
at the cell-surface, preventing their release and thus infection of other cells. Viruses have 
however developed means to counteract this restriction factor. Viral protein U (Vpu) is an 
accessory protein encoded by HIV-1, the causative agent of AIDS.  Vpu antagonizes 
Tetherin and consequently promotes the release of HIV-1 particles. A series of recent 
reports proposed that Vpu would induce the degradation of this restriction factor in order 
to overcome its anti-viral activity. Here, we report that Vpu is able to enhance HIV-1 
release in absence of Tetherin degradation. Instead, we found that Vpu interacts with 
Tetherin and interferes with the transport of the restriction factor towards the cell-surface. 
This would lead to re-localization of Tetherin in an intracellular organelle called the 
trans-Golgi network, resulting in insufficient levels of Tetherin at the cell-surface to trap 
progeny viruses. This mechanism of antagonism that results in TGN trapping could be 
augmented by the induction of degradation to effectively counteract the powerful 
restrictive effects of human Tetherin. Further characterization of this mechanism will 
improve our understanding of host antiviral defenses as well as provide new targets for 
the development of novel anti-HIV drugs. 
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Recent advances in retrovirology have revealed that mammalian cells do not 
always provide a hospitable environment for the replication of viruses that parasitize 
them. It is indeed becoming increasingly clear that mammalian cells express a variety of 
molecules and activities that interfere with specific steps of the replication cycle of 
retroviruses and other viruses [1]. Among these so-called restriction factors, the cellular 
protein CD317/BST-2/HM1.24, also designated as Tetherin in reference to its ability to 
tether HIV-1 virions to infected cells, was recently identified as a potent inhibitor of the 
release step of retroviruses [2,3]. Tetherin is a heavily glycosylated type II integral 
membrane protein with an unusual topology in that it harbors two completely different 
types of membrane anchor at the N- and C-terminus; it is composed of a short N-terminal 
cytoplasmic tail linked to a transmembrane anchor (TM), an extracellular domain that 
include three cysteine residues important for dimerization, a predicted coiled-coil and a 
putative C-terminal glycophosphatidyl-inositol (GPI)-linked lipid anchor that is believed 
to ensure incorporation of Tetherin into cholesterol-rich lipid rafts [4,5]. Tetherin inhibits 
the release of widely divergent enveloped viruses, including members of the lentivirus 
(primate immunodeficiency viruses), gammaretroviruses (murine leukemia virus), 
spumaretrovirus (foamy virus), arenavirus (Lassa virus), Filovirus (Ebola and Marburg 
virus) families as well as Kaposi’s sarcoma herpesvirus (KSHV) [2,3,6,7,8,9,10]. This 
broad-spectrum inhibition of enveloped virus particle release by Tetherin indicates that 
this restriction is unlikely to require specific interactions with viral proteins. In that 
regard, recent evidence indicates that Tetherin configuration rather than primary 
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sequences is critical for antiviral activity since an entirely artificial Tetherin-like protein 
consisting solely of domains from three proteins that were analogous to Tetherin in terms 
of size and topology but lacking sequence homology with native Tetherin, inhibited 
particle release in a manner strikingly similar to Tetherin [11]. Tetherin-mediated 
restriction of virus particle release is believed to occur at sites of virus particle assembly 
at the plasma membrane since a strong co-localization between Tetherin and nascent 
particles generated from retroviral or filoviral structural proteins was observed at the cell-
surface [7,12]. In fact, recent findings using the artificial Tetherin-like protein support a 
model of restriction in which Tetherin directly cross-links virions to the plasma 
membrane [11]. Under basal conditions, Tetherin is expressed in B and T cells, 
plasmacytoid dendritic cells and myeloid cells and many transformed cell lines 
[2,13,14,15,16]. In addition, Tetherin expression is induced in many cell-types by type I 
and type II interferon (IFN), which suggests that it might be an important component of a 
broader antiviral innate immune defense [2,13,17]. In response to this restriction, many 
viruses express Tetherin antagonists such as KSHV K5, Ebola virus envelope 
glycoprotein (GP), simian immunodeficiency virus (SIVmac/smm) Nef, HIV-2 Env, 
SIVtan Env and HIV-1 viral protein U (Vpu), which was the first anti-Tetherin factor 
identified [2,3,9,10,18,19,20,21,22].   
  Vpu is an oligomeric type 1 integral membrane protein with two major activities 
during HIV-1 infection [23]. It contributes to the down-regulation of the CD4 receptor by 
targeting newly synthesized CD4 molecules that are bound to envelope glycoproteins 
(Env) in the endoplasmic reticulum (ER) for degradation by the ubiquitin-proteasome 
system [24,25]. This degradation process relies on Vpu ability to associate with CD4 and 
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to recruit β-TrCP, a component of the SCFβ-TrCP E3 ubiquitin (Ub) ligase, via 
phosphorylation of serines 52 and 56 within its DSGΦXS β-TrCP recognition motif 
[26,27]. In addition, Vpu promotes HIV-1 particle release by suppressing human Tetherin 
activity in restrictive Tetherin-expressing cells such as epithelial cell lines (HeLa), T cell 
lines (Jurkat, CEM) and primary T lymphocytes and macrophages [2,3,17]. In contrast, 
no effect of Vpu is observed in permissive human cell lines devoid of Tetherin expression 
such as HEK 293T and HT1080. Interestingly, Vpu does not exert its anti-Tetherin 
activity in non-human cell lines regardless of their Tetherin expression levels [6,28]. 
Indeed, although Tetherin variants found in rhesus macaques, African green monkeys 
(agm) and mouse cells were able to inhibit HIV-1 particle release, they were resistant to 
antagonism by HIV-1 Vpu [29,30]. Analysis of Tetherin variants encoded by different 
species highlighted positively selected determinants in the Tetherin TM domain 
responsible for conferring sensitivity to Vpu antagonism [29,30,31,32]. The mechanism 
by which Vpu counteracts Tetherin antiviral activity on HIV-1 particle release is still a 
matter of debate. Vpu was found to decrease the expression of Tetherin at the cell-surface 
[3] and to prevent Tetherin and Gag co-localization at sites of particle assembly [7,12], 
suggesting that removal of Tetherin from its site of tethering action could underlie the 
mechanism by which Vpu counteracts this cellular restriction, although this model has 
lately been challenged [33]. Recently, a series of reports proposed proteasomal and/or 
endo-lysosomal degradation of Tetherin through a β-TrCP-dependent process as potential 
mechanisms by which Vpu antagonizes Tetherin antiviral activity [12,20,30,31,34,35]. 
However, in all of these studies, Vpu-induced Tetherin degradation did not entirely 
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account for the anti-Tetherin activity of Vpu. Thus, the precise mechanism(s) through 
which Vpu antagonizes Tetherin is yet to be elucidated. 
In this study, we investigated the effect of Vpu on Tetherin expression and 
trafficking to obtain a better insight into the mechanism through which Vpu antagonizes 
Tetherin-mediated restriction of HIV-1 particle release. Here, we provide evidence that 
Vpu can promote HIV-1 particle release without affecting the total steady-state levels or 
the turnover rate of Tetherin. We further show that even though Vpu did not enhance 
Tetherin internalization from the plasma membrane, it did significantly slow-down the 
transport of the restriction factor towards the cell-surface. Notably, expression of Vpu led 
to a specific removal of cell-surface Tetherin and a re-localization of the residual pool of 
Tetherin to a perinuclear compartment that extensively overlapped with the TGN. Finally, 
we show that Vpu and Tetherin associate most probably via their TM domains and 
provide evidence that this association is necessary to relocate Tetherin from the cell-
surface to the TGN and to counteract its restrictive activity on HIV-1 release. Overall, our 
results are consistent with a model whereby antagonism of Tetherin by Vpu involves 
sequestration of the restriction factor in a perinuclear compartment, away from virus 
assembly sites on the plasma membrane, a process that could be augmented by the 
induction of degradation. 
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Vpu can promote HIV-1 particle release without altering the steady-state levels or 
turnover of Tetherin    
To assess whether the reduction of Tetherin levels by Vpu was necessary and 
sufficient to promote efficient HIV-1 particle release, we analyzed the steady-state levels 
of fixed amounts of exogenously-expressed HA-Tetherin in permissive HEK 293T cells 
in conditions where varying levels of virally-encoded Vpu was co-expressed (Fig. 1A). 
This cellular system was previously used to evaluate the effect of Vpu on Tetherin 
steady-state levels [30,31,34]. At low Vpu expression levels (1 µg of Vpu+ proviral 
construct), the levels of Tetherin were essentially similar to those detected in absence of 
Vpu (1 µg of Vpu-defective proviral construct) (compare lane 5 with lane 6), while at 
higher levels of Vpu expression (2 µg of Vpu+ proviral construct), they were 
significantly reduced (compare lane 3 with lane 4). As expected, ectopic expression of 
HA-Tetherin strongly inhibited the release of Vpu-defective HIV-1 particle relative to the 
Tetherin-negative control as demonstrated by the drastic reduction of virion-associated 
p24 levels in the supernatants (Fig. 1A, compare lanes 3 and 5 with lane 1; quantified in 
Fig. 1B). Interestingly, although Vpu did not affect the total levels of exogenous HA-
Tetherin at low concentration, it still promoted efficient release of HIV-1 particle (Fig. 
1A, compare lane 5 with lane 6; quantified in Fig. 1B). These results suggest that Vpu 
can reduce the total levels of Tetherin, yet this process does not appear to be absolutely 
necessary to promote HIV-1 particle release.   
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To further confirm these observations, we analyzed the turnover of exogenously-
expressed native Tetherin in condition of efficient Vpu-mediated virus particle release by 
pulse-chase labeling analysis (Fig. 2A-C). HEK 293T cells were co-transfected with the 
proviral constructs HxBH10-vpu- or HxBH10-vpu+ and with a plasmid encoding native 
Tetherin. Forty-eight hours post-transfection, cells were pulse-labeled, chased for 
different intervals of time and analyzed for Tetherin and Vpu expression levels by 
sequential immunoprecipitation using specific antibodies (Abs). In parallel, transfected 
cells as well as virus-containing supernatants were collected prior to radio-labeling to 
monitor HIV-1 particle release by western blot. Tetherin-specific bands ranging from ~20 
kDa to ~29 kDa and likely representing putative glycosylated forms of monomeric 
Tetherin were immunoprecipitated (Fig. 2A). Ectopic Tetherin turnover was not altered 
by Vpu since none of the Tetherin-specific bands showed any significant accelerated 
reduction over time in the presence of the viral protein (Fig. 2A; compare lanes 7-10 with 
lanes 3-6). Quantitative analysis of Tetherin turnover revealed that exogenous Tetherin 
has a half-life of approximately 3.5h regardless of the presence of Vpu (Fig. 2B). 
Importantly, this lack of effect of Vpu on Tetherin turnover was observed in conditions of 
efficient Vpu-mediated HIV-1 particle release (Fig. 2C).  
We further evaluated the half-life of endogenous Tetherin in infected HeLa cells 
in the presence or absence of Vpu. Vesicular stomatitis virus glycoprotein G (VSV-G)-
pseudotyped HxBH10-vpu- or HxBH10-vpu+ virus-infected HeLa cells were pulse-
labeled, chased for different intervals of time and analyzed for Tetherin expression levels 
as described above. In this system, endogenous mature Tetherin was detected as a ~30-37 
kDa smear (Fig. 2D). A lower ~ 27 kDa band, distinct from the predicted Mr of 20 kDa 
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for unglycosylated Tetherin, was also detected at time 0 and most probably corresponds 
to immature glycosylated forms of newly synthesized Tetherin still residing in the ER. 
Exogenously- and endogenously-expressed Tetherin were recently reported to display 
distinct mobilities (~20-29 kDa  (Fig.2A) vs ~27 and 30-37 kDa (Fig.2D)) because they 
undergo different types of carbohydrate modifications [36]. Indeed, as demonstrated by 
Andrew and colleagues, we found that treatment of exogenous and endogenous Tetherin 
with Peptide: N-Glycosidase F (PNGase), an enzyme that cleaves all N-linked 
oligosaccharides, resulted in both cases in deglycosylated Tetherin proteins with a Mr of  
19-20 kDa that were recognized by our anti-Tetherin serum (data not shown).  
Figure 2D reveals that mature endogenous Tetherin has a half-life (t½) of 
approximatively 8h (Fig. 2D, lanes 1-5; quantified in Fig.2E), which is indeed longer than 
exogenously-expressed Tetherin (t½: 3.5h). Tetherin turnover was accelerated in presence 
of Vpu (t½: 3.5h) (compare lanes 6-10 to lanes 1-5; quantified in Fig. 2E), consistent with 
recent results reported by Douglas and colleagues using  HeLa cells transduced with Vpu-
expressing adenoviral vectors [20]. Since Vpu-mediated Tetherin degradation was 
reported to rely on its capacity to recruit β-TrCP [12,20,34,35], we evaluated the turnover 
of the restriction factor in presence of the β-TrCP-binding defective Vpu S52D,S56D 
mutant. This mutant harbors mutations at the key amino-acids required for interaction 
with β-TrCP (Ser52, and Ser56 for Asp) and displays a phenotype very similar to the 
well-characterized Vpu S52N,S56N mutant [3,12,20,27,33,35,37,38]. Notably, Vpu 
S52D,S56D is unable to mediate CD4 degradation [25] and to recruit β-TrCP (Fig. S1A), 
but is however able to partially down-regulate Tetherin from the cell-surface (Fig. S1B) 
and to promote HIV-1 particle release, albeit to a different extent than WT Vpu (Fig. 
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S1C-D).  Interestingly, even though Vpu S52D,S56D was still capable of promoting 
HIV-1 particle release, its expression did not affect Tetherin turnover (Fig.2D, compare 
lanes 11-15 and lanes 1-5; quantified in Fig. 2E), consistent with the reported role of β-
TrCP in Vpu-mediated Tetherin degradation [12,20,34,35]. Taken together, these results 
provide evidence that Vpu can promote HIV-1 particle release without a detectable 
reduction of Tetherin intracellular levels or a notable modification of its turnover, 
suggesting that reduction of total levels of Tetherin by a degradative process may not be 
necessary and/or sufficient to fully explain the anti-Tetherin activity of Vpu.  
 
 Vpu does not promote Tetherin endocytosis.  
Rodent Tetherin is internalized from the plasma membrane and delivered back to 
the TGN through a clathrin-dependent pathway that requires the sequential action of AP2 
and AP1 adaptor complexes [5]. Importantly, internalization was found to be dependent 
upon a dual tyrosine (Tyr)-based motif (YXXΦ, where Y corresponds to Tyr, the Xs are 
residues that are highly variable, and Φ corresponds to residues with bulky side chains) in 
the N-terminal cytoplasmic tail (amino acids at position 6 and 8) of the protein (Fig. 3A). 
One alternative mechanism to explain how Vpu down-regulates Tetherin cell-surface 
expression and counteracts its antiviral activity is by enhancing the rate of Tetherin 
endocytosis. To evaluate whether the natural pathway of Tetherin endocytosis was 
necessary for the anti-Tetherin activity of Vpu, we generated a mutant of Tetherin that 
harbored alanine substitutions at the two key Tyr residues within the dual Tyr-based 
internalization motif of the protein (HA-Tetherin Y6Y8) (Fig. 3A). Consistent with the 
previously reported role of this Tyr-based motif in rodent Tetherin endocytosis, 
12 
substitution mutation of Tyr6 and Tyr8 prevented HA-Tetherin from being efficiently 
internalized from the cell-surface (Fig. 3B). To assess whether mutation of the Tyr-based 
motif affected Tetherin sensitivity to Vpu, HEK 293T cells were co-transfected with 
HxBH10-vpu- or HxBH10-vpu+ proviral constructs and plasmids encoding for HA-
Tetherin or HA-Tetherin Y6Y8.  Even though HA-Tetherin Y6Y8 was expressed at 
higher levels at the cell-surface (mean fluorescence intensity (MFI) =240) as compared to 
HA-Tetherin wt (MFI=90), both proteins were down-regulated from the cell-surface by 
Vpu and indeed appeared to reach similar cell-surface steady state levels (MFI of 51 and 
41, respectively) (Fig. 3C). HIV-1 particle release was also monitored by western blot, 
48h post-transfection. Consistent with its higher cell-surface expression levels, the 
restriction of virus particle release was more pronounced in presence of HA-Tetherin 
Y6Y8 than with HA-Tetherin wt (Fig. 3D; compare lanes 5 and 3 with lane 1; quantified 
in Fig. 3D). It is interesting to note that the mutant protein was overall expressed at 
higher levels than the WT protein (Fig. 3D, compare lanes 5 and 3). This is likely the 
result of the inefficient clearance of HA-Tetherin Y6Y8, which is not efficiently 
internalized from the cell-surface. Nevertheless, Vpu was still proficient at overcoming 
the restricting activity of HA-Tetherin Y6Y8 on HIV-1 particle release as demonstrated 
by the increased levels of virion-associated p24 released in the supernatant (Fig. 3D, 
compare lane 6 with lane 5; quantified in Fig. 3E). Similarly, a 2h treatment with 10 µM 
chlorpromazine, a drug that blocks clathrin-coated pit assembly at the plasma membrane 
[39], did not affect the ability of Vpu to overcome Tetherin-mediated restriction of HIV-1 
particle release in HeLa cells (data not shown). Altogether, these results suggest that Vpu 
does not manipulate clathrin-mediated endocytosis, the natural pathway of Tetherin 
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endocytosis, as a mean to deplete the restriction factor from the cell-surface or to 
antagonize its antiviral activity. 
Since Vpu could accelerate Tetherin endocytosis by a clathrin-independent 
process, we next asked whether Vpu affected Tetherin internalization kinetics from the 
cell-surface using an assay that measures the contribution of all endocytosis pathways. To 
this end, we compared the rate of endocytosis of endogenous Tetherin in HeLa cells that 
were producing Vpu-positive HIV-1 (HxBH10-vpu+) with those producing a Vpu-
defective virus (HxBH10-vpu-) (Fig. 4). Consistent with previous studies of rodent 
Tetherin [5], human Tetherin was internalized constitutively. Interestingly, even though 
Vpu down-regulated Tetherin expression on the cell-surface (data not shown), the 
internalization kinetics of cell-surface Tetherin was unaffected (Fig. 4). These results 
indicate that Vpu does not counteract Tetherin restriction by promoting Tetherin 
endocytosis. 
 
Vpu interferes with Tetherin trafficking to the cell-surface. 
 We have recently reported that regulation of HIV-1 release correlates with co-
localization of Vpu and Tetherin in the TGN, thus raising the possibility that Vpu could 
act intracellularly by affecting Tetherin trafficking [40]. A cell-surface Tetherin re-
expression assay was developed to determine whether Vpu affects Tetherin trafficking to 
the cell-surface. Conceptually, this assay implies the loss of Tetherin epitopes at the cell-
surface and their subsequent recovery over time as demonstrated previously for analysis 
of the Mtv-1 Superantigen protein trafficking [41]. HeLa cells were co-transfected with 
the HxBH10-vpu- or HxBH10-vpu+ proviral constructs as well as with a GFP-encoding 
14 
plasmid to allow gating of transfected cells. Forty-eight hours post-transfection, cells 
were harvested and treated with pronase (0.05%) to proteolytically remove cell-surface 
protein epitopes.  After quenching the proteolytic reaction, stripped cells were incubated 
at 37°C for different time intervals to allow protein intracellular trafficking and re-
expression at the cell-surface and then stained at 4°C with anti-Tetherin Abs. Expression 
of Tetherin in transfected (GFP-positive) or untransfected (GFP-negative) subpopulations 
was analyzed by flow cytometry (Fig. 5). As expected, dot plots revealed that Tetherin 
levels were down-regulated by Vpu in the untreated cells (compare the GFP-
positive/HxBH10-vpu+ subpopulation MFI (MFI=36.8) with those of the GFP-
negative/HxBH10-vpu+ (MFI=56.7) or GFP-positive/HxBH10-vpu- (MFI=61.0) 
subpopulations) (Fig. 5A, untreated). Pronase treatment markedly reduced the levels of 
Tetherin at the cell-surface, indicating that Tetherin epitopes were efficiently removed 
from the cell-surface. Interestingly, the levels of Tetherin detected at time 0 in the GFP-
positive/HxBH10-vpu+ subpopulation was still lower (MFI=6.7) than those detected in 
the GFP-negative/HxBH10-vpu+ (MFI=9.7) or GFP-positive/HxBH10-vpu- (MFI=12.7) 
subpopulations (Fig. 5A, time 0 min). Similar levels of Tetherin re-expression was 
detected at the cell-surface of GFP-positive/HxBH10-vpu- cells and GFP-negative cells 
after 180 min of incubation as demonstrated by the comparable MFI detected in the two 
subpopulations. In contrast, Vpu caused a substantial reduction in Tetherin re-expression 
after 180 min, as shown by the lower MFI value in the GFP-positive/HxBH10-vpu+ 
population (MFI=19) compared to GFP-negative/HxBH10-vpu+ cells (MFI=38.1) (Fig. 
5A; 180 min).  Treatment of cells with 10 µM Brefeldin A (BFA), a fungal metabolite 
that blocks protein sorting from the ER to the Golgi, prevented efficient Tetherin re-
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expression at the cell-surface both in transfected (GFP-positive) and untransfected (GFP-
negative) cells, demonstrating the specificity of the re-expression assay (Fig. 5A, BFA).  
It is interesting to note that the absolute difference (∆) in MFI detected between the Vpu-
expressing cells and control cells (GFP-positive or negative/HxBH10-vpu- and GFP-
negative/HxBH10-vpu+) was amplified after 180 min (∆ = ~19) as compared to time 0 
(∆ = ~3-6), suggesting an effect of Vpu on cell-surface Tetherin re-expression kinetics. 
Indeed, the kinetics of Tetherin re-expression at the cell-surface, as measured by 
evaluating Tetherin levels (MFI) at the surface of pronase-treated cells  relative to the 
corresponding untreated GFP-negative control over 180 min, increased linearly in the 
GFP-positive/HxBH10-vpu- and was indistinguishable from that of the GFP-
negative/HxBH10-vpu+ control (slope of 0.27-0.29; Fig. 5B). After 180 min, 
approximately 75% of cell-surface Tetherin was recovered in both cases. In contrast, in 
presence of Vpu only ~35% of Tetherin expression was recovered at the cell-surface. 
Indeed, the kinetics of Tetherin re-expression in these Vpu-expressing cells was much 
slower than the controls (slope of ~0.14; Fig. 5B). Interestingly, the kinetics of Tetherin 
re-expression was similarly delayed in presence of the Vpu S52D,S56D mutant (slope of 
~0.11), indicating that the observed effect of Vpu on Tetherin re-expression at the cell-
surface is not the consequence of Tetherin degradation. Similar analysis based on the 
proportion of Tetherin-positive cells as a read-out (cut-off was arbitrarily set on the 
pronase-treated HxBH10-vpu+/GFP+ time 0 sample) revealed analogous results (data not 
shown). Thus, our results suggest that Vpu expression interferes with Tetherin trafficking 
along the secretory and/or recycling pathways.  
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Vpu expression causes a re-localization of the cellular pool of Tetherin in a 
perinuclear compartment 
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 To further support these observations and identify the intracellular compartment 
where Tetherin might accumulate in presence of Vpu, we analyzed the intracellular 
distribution of endogenous Tetherin in VSV-G-pseudotyped HxBH10-vpu- and HxBH10-
vpu+ virus-infected HeLa cells by immunostaining and confocal microscopy. To this 
end, we developed a staining protocol, which allowed simultaneous detection of Tetherin 
at the cell-surface and in intracellular compartments as described in the Materials and 
Methods. In the absence of Vpu, Tetherin was detected primarily at the plasma membrane 
but also to a lower extent on internal membranes that overlapped partially with TGN46, a 
cellular marker of the TGN (Fig. 6, Vpu- panels), consistent with previous intracellular 
localization studies of rodent Tetherin [4,13]. This localization pattern was drastically 
altered by the presence of Vpu, which caused an effective removal of Tetherin from the 
cell-surface without, however, significantly affecting the pool of proteins localized in the 
perinuclear compartment that co-stained with TGN46 (Fig. 6A, Vpu+ panels and Fig. 
6B). Notably, as reported previously by our laboratory [40], Vpu and Tetherin co-
localized extensively in the TGN. This altered localization pattern of Tetherin was not 
observed in neighbouring untransfected cells, which indeed displayed a strong Tetherin 
staining at the plasma membrane. Since we found that Vpu was accelerating Tetherin 
turnover in HeLa cells in a β-TrCP-dependent manner (Fig. 2D), we next analyzed the 
distribution of Tetherin in presence of the Vpu S52D,S56D mutant. In contrast to infected 
HeLa cells expressing WT Vpu, residual Tetherin was still readily detected at the plasma 
membrane of infected cells expressing the Vpu S52D,S56D mutant (Fig. 6A, Vpu 
17 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
S52D,S56D panels), a finding that most probably reflects the fact that this mutant is less 
efficient at down-regulating Tetherin from the cell-surface than WT Vpu (Fig. S1B). 
Interestingly, expression of this mutant resulted in a re-localization of the cellular pool of 
Tetherin in the TGN (Fig.6A). Importantly, Vpu S52D,S56D caused an ~4-fold increase 
of the absolute staining signal of Tetherin in the TGN relative to WT Vpu or the Vpu- 
control (Fig. 6B), suggesting that in absence of degradation, Vpu traps Tetherin in the 
TGN.  Taken together, these microscopy studies suggest that HIV-1 Vpu promotes the 
sequestration of endogenous Tetherin in the TGN, most probably before triggering β-
TrCP-dependent Tetherin degradation, thus preventing Tetherin’s trafficking to the 
plasma membrane.  Since these localization studies were performed in HIV-1-infected 
cells, these results further indicate that Tetherin sequestration occurs at physiological 
levels of Vpu expression. 
 
Association of Vpu and Tetherin involves their transmembrane anchor domains  
Having shown that Vpu expression affects the intracellular trafficking of Tetherin 
to the cell-surface and promotes a sequestration of Tetherin in the TGN, we next assessed 
whether Vpu can associate with Tetherin. HEK 293T cells were co-transfected with the 
HxBH10-vpu- or HxBH10-vpu+ proviral constructs as well as with a plasmid encoding 
HA-tagged Tetherin. Forty-eight hours post-transfection, cells were lysed in stringent 
detergent conditions with RIPA-DOC lysis buffer to avoid unspecific association 
resulting from membrane bridging. Tetherin was then immunoprecipitated from cell 
lysates with anti-Tetherin antibodies and the immunocomplexes were analyzed for the 
presence of Vpu by western blot. Immunoprecipitation of HA-Tetherin led to a selective 
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pull-down of the Vpu protein, suggesting that Vpu can directly or indirectly interact with 
Tetherin in cells where it can antagonize Tetherin antiviral activity (Fig. 7B, lane 8). 
Early studies aimed at mapping the regions of Vpu necessary for enhancing HIV-1 
release identified the TM domain of the protein as an important functional determinant 
since Vpu mutants that contained a randomized TM region (Vpu RD) or harbored point 
mutations within the TM spanning domain, such as Vpu KSL, failed to enhance virus 
particle release, yet were still stable, properly localized in a perinuclear compartment and 
able to induce efficient CD4 degradation [42,43]. Vpu KSL contains a three amino-acid 
substitution in which Ile6, Ile8, and Val9 were replaced by Lys, Ser, and Leu, 
respectively, and contains a positively charged amino-acid in an area that is devoid of 
charge. To evaluate whether Vpu interacted with Tetherin through the TM anchor 
domain, we performed similar co-immunoprecipitations in HEK293T cells co-transfected 
with a plasmid encoding HA-tagged Tetherin and proviral constructs encoding Vpu RD 
(HxBH10-vpu RD) or Vpu KSL (HxBH10-vpu KSL) (Fig. 7A).  In contrast to WT Vpu, 
both the Vpu RD and Vpu KSL mutants failed to co-immunoprecipitate efficiently with 
HA-Tetherin (Fig. 7B, compare lanes 9 and 10 with lane 8), suggesting that the 
association between the two proteins involves the TM domain of Vpu.  
Since the TM of Vpu represents an important determinant for the association with 
Tetherin, we next determined whether the TM domain of Tetherin was also involved. 
Tetherin TM was recently proposed to contain the determinants responsible for the 
species-specific sensitivity to Vpu [29,31,32]. Notably, reciprocal exchange of TM 
domains between human (h) and rhesus monkey Tetherin (THN) proteins conferred 
sensitivity and resistance to Vpu and alterations in the human Tetherin TM domain that 
19 
correspond to differences found in rhesus and agm Tetherin proteins were sufficient to 
render human Tetherin completely resistant to HIV-1 Vpu [29,31,32].  We constructed a 
set of expression plasmids encoding HA-tagged Tetherin chimeras with reciprocal 
exchanges of the TM between the human and agm proteins (Fig. S2A). In addition, we 
generated an expression plasmid encoding a HA-tagged human Tetherin that harbors 
double mutations in the TM domain (HA-human Tetherin ∆GI,T45I) comprising a 
deletion of Gly25 and Ile26 residues and substitution of Thr45 for an Ile (Fig. S2A). This 
mutant was previously reported to strongly inhibit HIV-1 particle release but was 
completely resistant to antagonism by Vpu [29]. HEK 293T cells were co-transfected 
with the HxBH10-vpu- or HxBH10-vpu+ proviral constructs as well as with the indicated 
HA-Tetherin-encoding plasmids (Fig. 7C-E). Forty-eight hours post-transfection, 
Tetherin was immunoprecipitated from cell lysates and immunocomplexes were further 
analyzed for the presence of Vpu by western blot. Since HA-agm Tetherin and the HA-
agmTHN(hTM) chimeras were less expressed and/or detected using our anti-human 
Tetherin Abs (these chimeras were not efficiently precipitated with  anti-HA Abs), Vpu 
association was compared between Tetherin variants displaying similar expression 
profile. As shown in Figure 7C, immunoprecipitation of HA-human Tetherin co-
precipitated Vpu (Fig. 7C, lane 12). As expected, HA-agm Tetherin, which was reported 
to be resistant to Vpu antagonism [29,32], did not show a strong and specific association 
with Vpu. In contrast, replacement of the agm Tetherin TM domain with that of human 
Tetherin (HA-agmTHN(hTM)) restored the association with Vpu (Fig. 7C, compare lane 
14 with lanes 16 and 12). Exchange of the human Tetherin TM with that of agm Tetherin 
(HA-hTHN(agmTM)) led to a marked reduction of Vpu association despite comparable 
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levels of Tetherin expression (Fig. 7D, compare lane 12 with lane 10). Finally, 
introduction of the ∆GI,T45I mutations in the TM domain of HA-human Tetherin 
drastically reduced the association with Vpu (Fig. 7E, compare lane 12 with lane 10). 
These results suggest that the integrity of the TM domain of human Tetherin is necessary 
for the association with Vpu. Taken together, our data suggests that association of Vpu 
and human Tetherin involves their TM anchor domains.  
 
Association of Vpu to Tetherin is required to down-regulate the expression of the 
restriction factor at the cell-surface and to promote HIV-1 particle release. 
 We next assessed whether association of Vpu to Tetherin was required to 
counteract Tetherin antiviral activity (Fig. 8). To do so, we transfected a proviral 
construct encoding WT Vpu or the Vpu KSL mutant in HeLa cells and first assessed their 
ability to associate with endogenous Tetherin. Wild type Vpu co-precipitated with 
endogenous Tetherin while Vpu KSL did not, confirming the results obtained when 
exogenous HA-tagged Tetherin was overexpressed in HEK293T cells expressing 
HxBH10-vpu+ or HxBH10-vpu KSL proviruses (Fig. 8A, compare lane 6 with lane 5). 
Association of Vpu with endogenous Tetherin was specific since HIV-1 envelope 
glycoprotein precursor gp160, another type 1 integral protein, did not co-precipitate with 
Tetherin (Fig. 8A). Interestingly, the Vpu KSL mutant was strongly attenuated in its 
ability to down-regulate efficiently the steady-state levels of Tetherin at the cell-surface 
relative to WT Vpu since Tetherin cell-surface expression in presence of Vpu KSL was 
significantly higher than in presence of WT Vpu (MFI of 191 vs 138), yet still slightly 
lower than in the Vpu-negative control (MFI= 235) (Fig. 8B). Importantly, as previously 
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reported [43], this mutant was drastically attenuated in its ability to promote efficient 
HIV-1 particle release (Fig 8C, compare lanes 3 and 2 with lane 1; quantified in Fig. 8D). 
Similarly to Vpu KSL, the Vpu RD mutant, which is also defective for Tetherin binding, 
was also markedly attenuated in its ability to down-regulate Tetherin cell-surface 
expression and to promote efficient HIV-1 release in HEK 293T cells ectopically-
expressing Tetherin (Fig. S3A and B), consistent with results reported by previous studies 
[3,42]. Human Tetherin containing the agm TM domain (HA-hTHN(agmTM)) or the 
∆GI,T45I mutations (HA-human Tetherin ∆GI,T45I) lost the ability to bind Vpu (Fig 7D 
and E) and as expected still restricted HIV-1 particle release even in the presence of Vpu 
(Fig. S2B and C for HA-hTHN(agmTM) and Fig. S2D and E for HA-human Tetherin 
∆GI,T45I). Unexpectedly, introduction of the human Tetherin TM domain in agm 
Tetherin (HA-agmTHN(hTM), did not reinstate a significant sensitivity to Vpu (Fig. S2 
B and C), despite a detectable restoration of the Vpu binding (Fig. 7C). This functional 
phenotype (absence of Vpu sensitivity) is different from that obtained by McNatt and 
colleagues [29] using agm or rhesus Tetherins containing the human Tetherin TM domain 
but is similar to that reported by Goffinet and colleagues [30] using rodent Tetherin 
proteins containing the human Tetherin TM domain. Difference in the configuration of 
the TM domain in these Tetherin chimeric constructs may explain this discrepancy. The 
result obtained with the HA-agmTHN(hTM) chimeric construct suggests that association 
of Tetherin with Vpu is necessary but not sufficient to overcome Tetherin-mediated 
restriction of HIV-1 particle release. However, we cannot rule-out the possibility that the 
binding of Vpu to the HA-agmTHN(hTM) chimeric protein may indeed be less efficient 
than with HA-human Tetherin since our antibody may underestimate the levels of 
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expressed HA-agmTHN(hTM) proteins  (Fig. 7C, compare lane 14 and lane 12). Thus, 
alternatively, a threshold level of Vpu association to Tetherin may be necessary to 
antagonize the antiviral activity of the restriction factor. Nonetheless, overall, these 
results suggest that association of Vpu to Tetherin is required to antagonize the antiviral 
function of the restriction factor.  
 
Association of Vpu to Tetherin is critical for the re-localization of the restriction 
factor in the TGN 
 Since we showed that expression of Vpu could cause a re-localization of Tetherin 
from the plasma membrane to the TGN, we next tested whether the Vpu TM domain 
mutants, Vpu RD and Vpu KSL, which are unable to associate with Tetherin, could still 
sequester endogenous Tetherin in the TGN. Hela cells were infected with VSV-G-
pseudotyped viruses expressing WT Vpu or Vpu RD or Vpu KSL and infected cells were 
immunostained and analyzed by confocal microscopy. Figure 9 reveals that both the Vpu 
RD and Vpu KSL lost the ability to efficiently remove Tetherin from the cell-surface and 
to relocate the restriction factor to the TGN. Indeed, quantitative analysis of the Tetherin 
signal localized in the TGN relative to the total cellular Tetherin signal showed that cells 
expressing the Tetherin degradation-defective Vpu S52D,S56D mutant displayed an 
increased proportion of Tetherin signal in the TGN compared to the Vpu- control. (~57% 
relative to ~18%; p<0.001) (Fig.6). In contrast, cells expressing the Vpu RD or Vpu KSL 
mutants showed ~25% of the Tetherin signal in the TGN, a proportion that was in fact 
just slightly higher than that found in cells infected with a Vpu-defective virus (Fig. 9).  
Accordingly, in contrast to Vpu S52D,S56D, these mutants did not show any increase in  
23 
the absolute levels of Tetherin signal in the TGN (Fig. 9).  These results indicate that Vpu 
promotes the sequestration of Tetherin in the TGN by a process that is dependent on the 
association of the two proteins. Taken together with the functional analysis and the co-
precipitation experiments, these results further suggest that the antagonism of Tetherin 
function by Vpu involves binding and sequestration of the restriction factor in the TGN. 
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The Vpu accessory protein stimulates the release of HIV-1 virions by 
antagonizing a restriction on virus particle release mediated by Tetherin at the cell-
surface [2,3]. This antagonism appears to closely correlate with the ability of Vpu to 
mediate down-regulation of Tetherin expression from the cell-surface [3,12,20].  While 
this down-regulation is accompanied by enhanced degradation of Tetherin in several 
infected cell types, such as Jurkat [20] and CEM-G37 T cells [21] or macrophages [33], 
several lines of evidence also suggest that degradation of Tetherin per se cannot entirely 
account for Vpu-mediated counteraction against the restriction factor since: 1) Vpu 
decreased total cellular Tetherin to a lesser extent than cell-surface Tetherin in HeLa cells 
[12]; 2) Vpu expression did not result in a reduction of intracellular Tetherin in infected 
CEMx174 and H9 cells, yet virus replication in these cells was Vpu-responsive [33]; 3) 
Vpu mutants that contained substitution mutation in the DSGΦXS β-TrCP recognition 
motif that rendered them deficient for directing β-TrCP-dependent degradation of 
Tetherin were still able to partially [3,12,20,34,37] (Fig. S1C and D) or in some instances 
totally [33,44] overcome the particle release restriction; 4) Binding of Vpu to Tetherin 
was recently shown to be sufficient for a partial relief of the restriction  [20,34].  
We show here that Vpu can promote efficient HIV-1 particle release without a 
detectable reduction of the total steady-state levels of Tetherin (Fig.1) nor a notable 
modification of the restriction factor turnover rate in transfected HEK 293T cells (Fig.2A 
-C), suggesting that degradation of the antiviral factor per se is not necessary and/or 
sufficient to account for Tetherin antagonism at least in this experimental system. 
25 
Interestingly, Vpu expression in HeLa cells increased endogenous Tetherin turnover (Fig. 
2D and E), as reported previously by Douglas and colleagues [20]. This Vpu-mediated 
degradation process was however still relatively slow (half-life of Tetherin decreases 
from ~8h to 3.5h in presence of Vpu) as compared to the very efficient CD4 receptor 
degradation induced by Vpu (half-life of CD4 decreases from ~6h to ~12 min in presence 
of Vpu) [45], and as such is unlikely to explain the powerful antagonism of Tetherin by 
Vpu. Thus, Vpu-mediated counteraction of Tetherin restriction must involve other 
mechanisms. Our results further indicate that Vpu does not promote endocytosis of 
Tetherin as a mechanism to antagonize the restriction factor. Indeed, mutation of the two 
critical tyrosine residues located within a dual tyrosine-based sorting motif in the 
cytoplasmic domain of the protein, did not abolish the sensitivity of Tetherin to Vpu, as 
was indeed recently reported by Iwabu and colleagues [35], yet led to an increased 
accumulation of the restriction factor at the cell-surface and to a more potent restriction 
of HIV-1 particle release (Fig. 3). Moreover, although analysis of Tetherin endocytosis 
kinetics showed that the protein is constitutively internalized, it did not reveal any 
increase in the rate of Tetherin endocytosis in presence of Vpu (Fig.4), and as such 
confirmed the results recently reported by Mitchell and colleagues [12]. These results are 
consistent with previous findings showing that Vpu-mediated enhancement of virus 
particle release is not significantly affected by expression of dominant negative (DN) 
mutants of Dynamin or Rab5 nor by depletion of clathrin heavy chain or by treatment 
with inhibitors of endocytosis such as chlorpromazine (data not shown) [6,40,46]. 
Collectively, they indicate that Vpu does not antagonize Tetherin by enhancing its 
endocytosis from the cell-surface. Instead, these findings suggest that Vpu affects 
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Tetherin anterograde trafficking events whose net effect is depletion of the restriction 
factor from the cell-surface. In support of this hypothesis, a previous report suggested that 
Vpu may acts as a regulator of protein transport along the secretory pathway [47]. In fact, 
upon analyzing the kinetics of Tetherin expression at the cell-surface of protease-treated 
HeLa cells, we noticed that Tetherin re-expression was significantly reduced in presence 
of Vpu (Fig. 5). It is important to note, here, that this effect is occurring regardless of 
whether Vpu is inducing Tetherin degradation in these experimental conditions since: 1) 
it is the rate of re-expression, as defined by the slope of the graph of figure 5B that is 
affected in presence of Vpu; 2) re-expression of cell-surface Tetherin was also delayed in 
presence of the Tetherin degradation-defective Vpu S52D,S56D mutant (Fig. 5B).  
Consistent with this observation, examination of infected HeLa cells expressing Vpu 
revealed that the cellular pool of Tetherin was re-localized from the cell-surface to a 
perinuclear compartment that stained positive with the TGN marker TGN46 and Vpu 
itself (Fig.6). Although some of the loss of cell-surface Tetherin in Vpu-expressing HeLa 
cells could be attributed to Vpu-mediated degradation of the restriction factor, similar 
experiments performed with the Vpu S52D,S56D mutant demonstrated that Vpu can 
cause a redistribution of Tetherin from the plasma membrane to the TGN. These results 
suggest that reduction of Tetherin levels at the plasma membrane involves a step whereby 
Vpu sequesters Tetherin in the TGN. They also provide a possible mechanism to explain 
the partial relief of Tetherin restriction observed by several groups upon expression of β-
TrCP-binding defective Vpu mutants [12,20,34].  However, since residual Tetherin was 
still readily detected at the plasma membrane of HeLa cells expressing the Vpu 
S52D,S56D mutant (Fig.6A and Fig.S1B), this sequestration may not be sufficient to 
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effectively prevent Tetherin to reach the cell-surface at least in this model. These 
observations underline, perhaps, the need for β-TrCP-mediated trafficking and 
degradation processes as a complementary mechanism to efficiently remove Tetherin 
from the cell-surface, particularly in certain cell types or under specific conditions, such 
as IFN exposure, where cellular Tetherin expression levels are high. Thus, the different 
particle release phenotypes observed with Vpu mutants that are unable to recruit β-TrCP, 
such as Vpu S52D,S56D, (these range from as efficient than WT Vpu to a ~50% 
attenuation) [3,12,20,33,34,37,44] may in fact relate to differing levels of Tetherin 
expression in the target cells. Although, it is conceivable that Vpu-mediated sequestration 
of Tetherin in the TGN may explain how Vpu antagonizes Tetherin in the absence of a 
decrease in total Tetherin expression, it still remains unclear how Vpu could antagonize 
Tetherin in the absence of down-regulation from the cell-surface and a decrease in total 
cellular expression in certain cell types [33].  
We also confirmed by co-immunoprecipitation studies that Vpu interacts with 
Tetherin [20,32,34,35] and demonstrated using well-characterized Vpu and Tetherin 
mutants as well as chimeric proteins between human and African green monkey Tetherin 
molecules that this physical interaction involves the transmembrane domains of the two 
proteins (Fig. 7 and Fig. 8). These findings are consistent with previous results showing 
that the transmembrane domain of Vpu is required for both the down-regulation of  
surface Tetherin and the enhancement of  HIV-1 particle release [3,42,43]. They are also 
supported by recent data indicating that the inability of Vpu to antagonize the restrictive 
effect of African green monkey and rhesus Tetherin proteins is a consequence of amino-
acid changes in the transmembrane domain of the rhesus and African green monkey 
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protein relative to the human form [29,32].  Importantly, our data establish a direct 
functional link between association of Vpu to Tetherin and Tetherin antagonism since we 
showed that Vpu’s ability to interact with Tetherin was necessary:  1) to counteract the 
restriction on HIV-1 particle release and down-regulate Tetherin from the cell-surface 
(Fig. 8, Fig. S2 and S3); and, 2) to induce a re-localization of the cellular pool of Tetherin 
from the plasma membrane to the TGN (Fig. 9).  Unexpectedly, our observation showing 
that introduction of the human Tetherin TM domain in African green monkey Tetherin 
did not reinstate a significant sensitivity to Vpu (Fig, S2B and C) despite a detectable 
restoration of the Vpu binding raises the possibility that this interaction may not be 
sufficient to explain Tetherin antagonism. The requirement for additional cellular 
factor(s) in the Vpu-mediated Tetherin antagonism is therefore a possibility that warrants 
further investigations.   
Since our co-immunoprecipitation and functional data indicate that a physical 
interaction between Vpu and Tetherin is required for Tetherin antagonism and 
sequestration, this raise the possibility that Vpu may simply interact with Tetherin and 
inhibit its outward trafficking from the TGN since all membrane proteins are transported 
to the plasma membrane through the TGN (Fig. 10). Since mutation of the dual Tyr 
signal in the Tetherin cytoplasmic tail does not abolish the sensitivity to Vpu, it appears 
that Tetherin sequestration in the TGN may occur before its endocytosis from the cell-
surface and as such may involve newly synthesized Tetherin en route to the plasma 
membrane. However, we cannot completely rule-out that Vpu could interact with 
endocytosed Tetherin in the TGN and prevent its recycling back to the cell-surface, given 
that previous data from the Spearman group demonstrated a requirement for the recycling 
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endosomes in Vpu function [48]. Furthermore, recent studies reported that AP-2 
depletion [12] or over-expression of DN mutant of Dynamin (Dyn2-K44A) [35] could 
partially interfere with Vpu-mediated down-regulation of Tetherin expression from the 
cell-surface.  Indeed, since Vpu is expressed from a Rev-dependent bicistronic mRNA 
encoding Env and consequently is made late during the virus life cycle [49], the direct 
removal of Tetherin from the plasma membrane via endosomal trafficking may be critical 
to ensure a rapid and efficient neutralization of the restriction on HIV-1 release. It is 
nevertheless surprising that mutation of the Tetherin dual Tyrosine-based endocytosis 
motif did not affect the ability of Vpu to counteract Tetherin-mediated restriction of HIV-
1 particle release. Perhaps co-expressing transiently the two proteins simultaneously may 
not adequately reflect physiological conditions given that Tetherin is normally already 
present at the plasma membrane when Vpu is expressed. Alternatively, it is also possible 
that sequestration of newly synthesized Tetherin in the TGN may rapidly clear the 
restriction factor from its site of virion-tethering action at the plasma membrane 
depending on the physiologic rate of Tetherin turnover at the plasma membrane. More 
studies will be required to assess whether Vpu affects Tetherin trafficking at a pre- or/and 
post-endocytic step.               
Vpu-mediated sequestration of Tetherin in the TGN could be complemented by β-
TrCP-dependent degradation processes, thus enhancing Tetherin antagonism.  It is 
conceivable that Vpu by forming a complex with β-TrCP and Tetherin in the membrane 
of the TGN could potentially induce ubiquitination via interaction with the SCFβ-TrCP E3 
ubiquitin ligase. This ubiquitination event could either enhance the sequestration by 
preventing Tetherin recycling to the cell-surface or/and targets it to lysosomes for 
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degradation (Fig.10). Our data indicating that Vpu causes a re-localization of the cellular 
pool of Tetherin in the TGN, where indeed the two proteins strongly co-localize, suggests 
that Vpu affects Tetherin trafficking and potentially its degradation from a post-ER 
compartment(s), and as such is difficult to reconcile with a mechanism of proteasomal 
degradation of the antiviral factor through the cellular ER-associated degradation 
(ERAD) pathway [30,31,34]. However, given the fact that Vpu induces degradation of 
the CD4 receptor in the ER by an ERAD-like mechanism [25], it is still possible that 
some proteasomal degradation in the ER may contribute to Tetherin depletion.  Whether 
Vpu and Tetherin trafficking cross each other in the TGN, thus permitting a physical 
interaction between the two proteins, remains to be determined. In this regard, it is 
interesting to note that recent data from our laboratory have shown that the ability of Vpu 
to suppress Tetherin-mediated restriction of HIV-1 particle release was linked to its 
localization in the TGN [40]. Further studies aimed at identifying the determinants 
regulating Vpu trafficking and localization in the TGN will likely shed light on this 
mechanism.   
HIV-1 Vpu appears to share the ability to sequester Tetherin in the TGN with 
other Tetherin antagonists, namely HIV-2 Rod and SIVtan Env. Like HIV-1 Vpu, HIV-2 
Rod Env was recently shown to interact with Tetherin and to cause a redistribution of 
Tetherin in the TGN, although in the case of HIV-2 Env, no evidence of Tetherin 
degradation was observed [21]. Similarly, SIVtan Env was also shown to downregulate 
cell-surface Tetherin by sequestering the restriction factor in intracellular compartment(s) 
[22]. Collectively, these findings suggest a common mechanism of antagonism that 
results in TGN trapping, which can be augmented by the induction of degradation in the 
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case of Vpu. Given the powerful restrictive effects of human Tetherin on HIV production, 
this dual mechanism of antagonism mediated by Vpu may have provided HIV-1 with 
stronger countermeasures to antagonize Tetherin. This genetic and functional divergence 
between HIV-1 and HIV-2 may perhaps account for the different virulence properties 
displayed by these two closely related viruses [21,50].  Future studies on the role of 
Tetherin antagonism in the pathogenesis of primate immunodeficiency virus will likely 
shed light on the contribution of this innate antiviral factor in the control of viral infection 
and spread in vivo and will reveal whether enhancing the antiviral activity of Tetherin is a 
valid option to thwart HIV-1 replication.        
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Antibodies and chemical compounds.  Anti-Vpu rabbit polyclonal serum was described 
previously [40]. Anti-Tetherin rabbit polyclonal serum was generated by immunization of 
rabbits with a bacterially-produced Glutathione-S-transferase (GST) fusion protein 
containing a polypeptide corresponding to amino-acids 40 to 180 of human Tetherin. 
Rabbit pre-immune serum was collected prior to rabbit immunization. Monoclonal anti-
HA (clone 12CA5), anti-p24 (catalog no. HB9725) and anti-myc (clone 9E10) Abs were 
isolated from the supernatants of cultured hybridoma cells obtained from the American 
Type Culture Collection (ATCC). The monoclonal anti-gp120 antibody [51,52] was 
obtained from NIH AIDS research and Reference Reagent Program.  All secondary 
Alexa-conjugated IgG Abs were obtained from Invitrogen. Sheep anti-TGN46 (Serotec), 
mouse anti-BST2 (Abnova), anti-actin Abs (Sigma), pronase (Calbiochem), PNGase 
(New England Biolabs), BFA, paraformaldehyde (PFA) and chlorpromazine (Sigma) 
were all obtained from commercial sources. All reagents were stored according to the 
manufacturer’s instructions.  
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Cells and transfection.  HEK 293T, HeLa and Cos-7 cells were obtained from ATCC. 
All cells were maintained as described previously [40]. HEK 293T and HeLa cells were 
transfected using the calcium-phosphate method and lipofectamine 2000 (Invitrogen), 
respectively. Functional and biochemical analyses were performed 48h post-transfection. 
Empty plasmid DNA was added to each transfection to keep the amount of transfected 
DNA constant.   
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Plasmid constructs.  HxBH10-vpu+ and HxBH10-vpu- are two infectious molecular 
clones of HIV-1 that are isogenic except for the expression of Vpu [53]. HxBH10-vpu 
S52D,S56D, SVCMV-vpu- and SVCMV-vpu+ were previously described, [25]. 
HxBH10-vpu KSL, HxB10-vpu RD and SVCMV-vpu S52D,S56D were generated by 
PCR-based site-directed mutagenesis [40]. The pcDNA/Myc-His-β-TrCP plasmid was 
kindly provided by Dr. Richard Benarous [27].  To generate pcDNA-Tetherin and 
pCMV-HA-Tetherin, the human Tetherin open reading frame was amplified by PCR 
from pCMV-SPORT6-hBST2 plasmid (Open Biosystems) and cloned into 
pcDNA3.1/Hygro (+) (Invitrogen) and pCMV-HA (Clontech). The agmTetherin open 
reading frame was amplified from Cos-7 cells mRNA using RT-PCR as described [29]. 
Tetherin chimeras were designed according to the structure prediction from Kupzig and 
Banting [4]. All Tetherin genes were inserted into pcDNA3.1/Hygro (+) using NheI and 
Asp718 restriction sites or into the pCMV-HA plasmid using BglII and Asp718 
restriction sites to generate pcDNA-Tetherin and pCMV-HA-Tetherin constructs, 
respectively. pCMV-HA-Tetherin Y6Y8 and pCMV-HA-Tetherin ∆GI,T45I were 
generated by PCR-based site-directed mutagenesis. The vesicular stomatitis virus (VSV) 
glycoprotein G-expressing plasmid, pSVCMVin-VSV-G, was previously described [54]. 
The pQBI25 GFP-expressing plasmid was obtained from Qbiogene. 
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Steady-state detection of proteins by western blot.  Transfected HeLa or HEK 293T cells 
were lysed in CHAPS lysis buffer (50 mM Tris, 5 mM EDTA, 100 mM NaCl, 0.5% 
CHAPS, pH 7.2) or in radio-immunoprecipitation assay (RIPA-DOC) buffer (10 mM Tris 
pH 7.2, 140 mM NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 1% Nonidet-P40, 0.5% sodium 
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dodecyl sulfate, 1.2 mM deoxycholate), respectively. Proteins from lysates were resolved 
on 12.5% SDS-PAGE, electro-blotted and analyzed by western blot as described 
previously [40]. 
 
Pulse-chase and radio-immunoprecipitation experiments.  Pulse-chase experiments 
were perfomed as described previously [40]. Briefly, transfected HEK 293T or HeLa 
cells infected with VSV-G-pseudotyped HxBH10-derived virus at a MOI of 1 were 
pulse-labeled for 30 min and 2h respectively, with 800 µCi/ml of [35S]methionine and 
[35S]cysteine (Perkin Elmer) and chased for different interval of times. Following lysis of 
radio-labeled cells in RIPA-DOC, lysates were first pre-cleared with protein A sepharose 
beads coated with pre-immune rabbit serum for 1h. Pre-cleared cell lysates were then 
incubated with anti-Tetherin Abs for 2h at 4°C prior to immunoprecipitation using 
protein A sepharose beads. In HEK 293T cells, Vpu proteins were sequentially 
immunoprecipitated using the same method. Labeled proteins were analyzed by SDS-
PAGE and autoradiography. 
 
PNGase treatment. Cells were lysed in RIPA-DOC. Tetherin-containing lysates were 
incubated with anti-Tetherin Abs for 2h at 4°C prior  to addition of protein A sepharose 
beads. Following an incubation of 2h at 4°C, beads were isolated by centrifugation, 
washed with denaturing buffer (New England Biolabs), resuspended in denaturing buffer 
and then boiled at 95°C for 10 min.  The supplied reaction buffer was added along with 
NP-40 (0.1%) according to the manufacturer’s suggestion. Samples were then digested 
with 1500 units of PNGase (New England Biolabs) at 37°C for 3h. Control samples were 
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incubated without the enzyme. Proteins were eluted from beads by boiling in an equal 
volume of sample buffer for 10 min and analyzed by immunoblotting.   
 
Virus release assay.  The virus release assay was described previously [40]. Briefly, 
supernatants of transfected cells were clarified by centrifugation and filtered through a 
45µm filter. Viral particles were pelleted by ultracentrifugation onto a 20% sucrose 
cushion in PBS for 2h at 130000 g at 4°C and lysed in RIPA-DOC. Gag products were 
analyzed by western blot. Viral release efficiency was evaluated by determining the ratio 
between the virion-associated Gag (p24) band signal and all intracellular Gag-related 
band signal using laser scanning densitometry.  
 
Production of VSVg-pseudotyped HIV-1 virus. HEK 293T cells were transfected with 
HxBH10 proviral constructs and pSVCMVin-VSV-G as described previously [54]. 
Supernatants of transfected cells were clarified, filtered and pelleted by 
ultracentrifugation as described above and resuspended in DMEM supplemented with 
10% bovine serum (FBS). Viruses were titrated using a standard MAGI assay [54].   
 
Flow cytometry.  Cells were washed in PBS, resuspended at a concentration of 
1x106cells/ml and stained with the specific anti-Tetherin serum for 45 min at 4°C. After 
incubation, cells were washed and stained using appropriate fluorochrome-coupled 
secondary Abs for 30 min at 4°C. Cells were then washed, fixed with 2% PFA. 
Transfected GFP-expressing cells were analyzed for cell-surface Tetherin expression by 
flow cytometry. Rabbit pre-immune serum served as a staining control. Fluorescence 
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intensities were acquired using a FACScalibur flow cytometer (BD Biosciences) and data 
was analyzed using FlowJo software v. 7.25 (Treestar). MFI values presented in the 
histograms correspond to the specific signal obtained after substraction of the MFI value 
from the pre-immune control. 
 
Internalization assay. Cells were washed in PBS, re-suspended in PBS containing the 
anti-Tetherin serum at a concentration of 1x106cells/ml and incubated for 45 minutes at 
4°C. Following washes in cold PBS, cells were incubated at 37°C in DMEM medium 
supplemented with 5% FBS for different time intervals. At each time point, cells were 
harvested, washed in cold PBS and stained with the appropriate fluorochrome-coupled 
secondary Abs for 30 min at 4°C. Transfected GFP-expressing cells were analyzed for 
cell-surface Tetherin expression by flow cytometry. 
 
Cell-surface Tetherin re-expression assay.  Cells were harvested, washed in PBS, re-
suspended at a concentration of 1x106 cells/ml in PBS-pronase 0.05% and incubated for 
30 minutes at 37°C. Cold DMEM containing 10% FBS was added to block surface 
protein proteolysis. Cells were then washed, incubated at 37°C for different time intervals 
and stained for cell-surface Tetherin as described above. Expression of Tetherin at the 
cell-surface of transfected GFP-positive and untransfected GFP-negative cells was 
analyzed by flow cytometry.  
 
Confocal microscopy.  HeLa cells were infected with VSV-G-pseudotyped HxBH10-
derived viruses at a MOI of 0.125. Forty-eight hours post-infection, cells were 
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immunostained with anti-Tetherin Abs (Abnova) for 30 min at 4°C, washed in cold PBS, 
fixed with 4% PFA and permeabilized with 0.2% Triton X-100. Next, cells were 
incubated with anti-Tetherin (Abnova), anti-Vpu and anti-TGN46 Abs for 2h at 37°C, 
washed and incubated with the appropriate secondary Abs for 30 min at room 
temperature. Analyses were performed with a LSM710 laser scanning confocal 
microscope (Zeiss).
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 Quantitation of Tetherin signal was performed using the Zeiss 
LSM510 software. The absolute Tetherin signal in the TGN was determined by 
measuring the specific Tetherin signal in the region delineated by the TGN46 marker on 
digital pictures produced using similar acquisition time. Percentage of Tetherin 
accumulating in the TGN was calculated by evaluating Tetherin signal intensity in the 
TGN relative to the total Tetherin signal intensity detected in the cell as described 
previously [40]. Analysis was performed on at least 25 distinct cells. 
 
Co-precipitation assay. For co-immnuoprecipitation of Vpu and Tetherin, transfected 
HEK 293T and HeLa cells were harvested 48h post-transfection and lysed in RIPA-DOC 
or CHAPS buffer, respectively. Five percent of the lysate was preserved to control for 
protein expression. Cell lysates were first pre-cleared with protein A sepharose beads 
coated with pre-immune rabbit serum for 1h at 4°C and then, incubated with anti-
Tetherin Abs for 2h at 4°C, prior to precipitation with protein A sepharose beads. 
Immunoprecipitates were analyzed for the presence of Vpu and Tetherin by western blot.  
For co-immunoprecipitation of Vpu and β-TrCP, HEK 293T cells were transfected with 
SVCMV-vpu- or SVCMV-vpu+ or SVCMV-vpu S52D,S56D and pcDNA/Myc-His-β-
TrCP.  Transfected cells were then radiolabelled with 800 µCi/ml of [35S]methionine and 
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[35S]cysteine (Perkin Elmer) and lysed in CHAPS buffer. Lysates were first pre-cleared 
with protein A sepharose beads coated with pre-immune rabbit serum for 1h. Pre-cleared 
cell lysates were then incubated with anti-myc Abs for 2h at 4°C prior precipitation using 
protein A sepharose beads. Vpu was then sequentially immunoprecipitated using anti-
Vpu Abs using the same method. Labeled proteins were analyzed by SDS-PAGE and 
autoradiography. 
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Scanning and quantitation.  Scans were performed on a Duoscan T1200 scanner 
(AGFA) followed by densitometric quantitation using the Image Quant 5.0 software 
(Molecular Dynamics).  Statistical analysis was performed using a paired Student’s t test, 
and statistical significance was considered at p <0.001. 
 
 Accession numbers: NCBI reference number for HxBH10 Vpu and human Tetherin 
proteins are P69699 and AAH33873, respectively. Genebank accession number for agm 
Tetherin is FJ943430.  
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Figure 1: Enhancement of viral particle release in absence of Vpu-dependent 
reduction of Tetherin steady-state levels.  
HEK 293T cells were co-transfected with a fixed amount of the HA-Tetherin-expressing 
plasmid (235 ng) and the indicated amounts of HxBH10 proviral constructs. Forty-eight 
hours post-transfection, cells and virus-containing supernatants were harvested and 
processed for western blot analysis. (A) Proteins in the viral and cell lysates were 
detected using specific Abs. (B) Quantification of HIV-1 release efficiency. Bands 
corresponding to Gag products in cells and viral particles in panel (A), as detected using 
anti-p24 Abs, were scanned by laser densitometry. The virus particle release efficiency 
was determined as described in the Materials and Methods and calculated as a percentage 
of the release of  HxBH10-vpu+ (100%) in absence of HA-Tetherin. The values within 
the graph represent the fold increase of virus particle release upon Vpu expression. 
 
Figure 2: Analysis of the turnover of endogenous and exogenously-expressed 
Tetherin in the presence of Vpu.  
(A-C) Turnover of exogenously-expressed Tetherin. (A) HEK 293T cells were co-
transfected with the indicated HxBH10 proviral constructs and the pcDNA-Tetherin 
plasmid.  Forty-eight hours post-transfection, cells were pulse-labeled and chased for the 
indicated time intervals. Tetherin and Vpu were immunoprecipitated with specific Abs, 
and analyzed by autoradiography. The asterisk indicates the presence of a non-specific 
signal. (B) Quantitation of (A). The graph represents the percentage of Tetherin 
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recovered relative to time 0. The signal intensity of all Tetherin-specific bands was 
determined for each time point by densitometric scanning.  The percentage of Tetherin 
recovered was calculated as the ratio of the Tetherin bands signal at a given time relative 
to the signal at time 0. Error bars indicate the standard deviation of the mean from 2 
independent experiments. (C) Virus-containing supernatant and a fraction of the cells 
from (A) were collected prior to labeling. Gag proteins from the cell and viral lysates 
were analyzed by western blot using anti-p24 Abs. (D-E) Turnover of endogenous 
Tetherin. (D) HeLa cells were infected with the indicated VSV-G-pseudotyped HxBH10 
virus. Forty-eight hours post-infection, cells were pulse-labeled and chased for the 
indicated time intervals. Tetherin was immunoprecipitated with specific Abs, and 
analyzed by autoradiography. Vpu and actin were detected by western blot from cell 
lysates harvested prior to labeling. (E) Quantitation of (D) as described in (B). Full black 
line: HxBH10-vpu+; Dashed line: HxBH10-vpu-; Full grey line: HxBH10-vpu 
S52D,S56D. 
 
Figure 3:  Mutation of Tetherin dual Tyrosine-based sorting motif does not affect 
sensitivity to Vpu  
(A) Schematic representation of HA-Tetherin wt and HA-Tetherin Y6Y8.  The 
overlapping Tyr-based motifs are presented in the grey box.  X and Φ correspond to 
variable and hydrophobic amino-acid residues, respectively. Hyphens represent 
unchanged amino-acids. The site that is cleaved prior to addition of the GPI lipid anchor 
is represented by the dashed line.  Glycosylation sites are represented at position 65 and 
92. (B) Kinetics of HA-Tetherin Y6Y8 internalization. HEK 293T cells were co-
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transfected with the indicated HxBH10 constructs and a GFP-expressing plasmid.  Forty-
eight hours post-transfection, cell-surface Tetherin was labeled with Tetherin specific 
Abs at 4°C before incubating cells at 37°C for the indicated time intervals to allow 
endocytosis. Cells were then incubated at 4°C in presence of appropriate secondary Abs.  
The graph depicts the relative levels of Tetherin at the surface of GFP-expressing cells 
(time 0 = 100%) and represents the loss of Tetherin-specific signal following 
endocytosis. (C) Cell-surface expression of HA-Tetherin Y6Y8. HEK 293T cells were 
co-transfected with the indicated HA-Tetherin plasmid and HxBH10 proviral constructs 
in presence of a GFP-expressing plasmid. Cell-surface Tetherin expression was analyzed 
on GFP-positive cells by flow cytometry 48h post-transfection.  Geo mean values 
(depicted as MFI) are shown.  Full lines: HxBH10-vpu+; dashed lines: HxBH10-vpu-; 
filled histogram: pre-immune control. The results are representative of two independent 
experiments. (D) Effect of HA-Tetherin Y6Y8 on HIV-1 particle release. HEK 293T 
cells were co-transfected with the indicated HxBH10 proviral constructs and HA-
Tetherin-expressing plasmids. Forty-eight hours post-transfection, transfected cells and 
virus-containing supernatants were harvested.  Proteins from cell and viral lysates were 
analyzed by western blot using specific Abs. (E) Quantitation of HIV-1 particle release. 
Bands corresponding to Gag products in cells and viral particles were scanned by laser 
densitometry. The virus particle release efficiency was determined as described in the 
Materials and Methods and calculated as a percentage of the release of  HxBH10-vpu+ 
(100%) in absence of HA-Tetherin. Error bars indicate the standard deviation of the mean 
from two independent experiments. 
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Figure 4: Vpu antagonizes Tetherin without promoting its endocytosis.  1 
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HeLa cells were co-transfected with the indicated HxBH10 constructs and a GFP-
expressing plasmid.  Forty-eight hours post-transfection, cell-surface Tetherin was 
labeled with Tetherin specific Abs at 4°C before incubating cells at 37°C for the indicated 
time intervals to allow endocytosis. Cells were then incubated at 4°C in presence of the 
appropriate secondary Abs.  The graph depicts the relative levels of Tetherin at the 
surface of GFP-expressing cells (time 0 = 100%) and represents the loss of Tetherin-
specific signal resulting from endocytosis.  Error bars indicate the standard deviation of 
the mean from two independent experiments.  
 
Figure 5: Vpu affects Tetherin trafficking to the cell surface. 
(A-B) HeLa cells were transfected with the indicated HxBH10 proviral constructs and a 
GFP-expressing plasmid.  Forty-eight hours post-transfection, cells were harvested and 
treated with pronase (0.05%). After quenching of the proteolytic reaction, cells were 
cultured at 37ºC for different time intervals and then immunostained for cell-surface 
Tetherin. (A) Dot plots representing cell-surface Tetherin levels relative to GFP 
expression.  MFI values are presented for each gate.  Treatment with BFA (10 µM) 
served as a positive control for intracellular retention. BFA was added to the media 
immediately after treatment with pronase and kept throughout the chase period. (B) 
Quantitative representation of panel (A). Kinetics of Tetherin re-expression were 
determined by calculating the percentage of Tetherin expression (MFI) at the surface of 
pronase-treated cells relative to the corresponding untreated GFP-negative control at 
different time intervals. Equations pertaining to each linear equation are shown above the 
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graph. Error bars represent the standard deviation of at least two separate experiments.  
Black dashed line: HxBH10-vpu+/GFP-; Black full line: HxBH10-vpu-/GFP+; Red full 
line: HxBH10-vpu+/GFP+; Blue full line: HxBH10-vpu S52D,S56D/GFP+. Similar 
results were obtained when the proportion of cells expressing Tetherin at the cell-surface 
was used as a read-out instead of Tetherin MFI. For these latter analyses, the cut-off was 
arbitrarily set on the pronase-treated HxBH10-vpu+/GFP+ time 0 sample (illustrated by 
the dotted line in Figure 5A) so that the background level of Tetherin-positive cells 
corresponded to 1%. 
 
Figure 6: Vpu expression causes a re-localization of the cellular pool  of Tetherin in 
a perinuclear compartment. 
HeLa cells were infected with VSV-G pseudotyped HxBH10-vpu-, HxBH10-vpu+ or 
HxBH10-vpu S52D,S56D virus. Forty-eight hours post-infection, cells were 
immunostained for cell-surface Tetherin, fixed, permeabilized and co-stained with anti-
Tetherin (red), anti-Vpu (green) and anti-TGN46 (blue) specific Abs. Nuclei were 
counterstained with DAPI (cyan). Cells were observed by confocal microscopy. The 
white scale bar represents a distance of 10 µm. (B) Quantitation of the absolute Tetherin 
signal in the TGN was determined by measuring the specific Tetherin signal in the region 
delineated by the TGN46 marker on digital picture produced using similar acquisition 
time. Error bars indicate the standard deviation of the mean from the quantitative analysis 
of at least 25 distinct cells per conditions. 
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Figure 7: Association of Vpu and Tetherin involves their transmembrane anchor 
domains. 
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(A) Schematic representation of WT Vpu, Vpu KSL and Vpu RD. The TM domain is 
represented by the unfilled box while the cytosolic domain with the two predicted 
α−helices (H-1 and H-2) is indicated by the filled box. Phosphorylation sites are 
represented by the small circles. The amino-acid sequence of the TM anchor region is 
represented below. Hyphens represent identical amino-acids. (B-E) Co-
immunoprecipitation experiments of Tetherin and Vpu. (B) HEK 293T cells were 
transfected with a HA-human Tetherin-expressing plasmid and the indicated HxBH10-
derived proviral constructs. Forty-eight hours post-transfection, cells were lysed and 
proteins were co-immunoprecipitated using anti-Tetherin Abs.  Co-immunoprecipitated 
proteins were analyzed by western blot using anti-Tetherin and anti-Vpu Abs. (C-E) HEK 
293T cells were transfected with the indicated HA-Tetherin-expressing plasmids and the 
specified HxBH10 proviral constructs. Forty-eight hours post-transfection, cells were 
lysed and proteins were co-immunoprecipitated and analyzed as described above. In (D), 
HA-Tetherin proteins were revealed by western blot using anti-HA Abs. Amounts of 
protein in the lysate prior to immunoprecipitation (input) is shown in the left panels. Non-
specific bands, depicted by the asterisks, were used as loading controls.  
 
Figure 8:  Association of Vpu to Tetherin is required to antagonize the antiviral 
activity of the restriction factor. 
(A) Association of Vpu with endogenous Tetherin. HeLa cells were transfected with the 
indicated HxBH10 proviral constructs.  Forty-eight hours post-transfection, cells were 
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lysed and proteins were co-immunoprecipitated using anti-Tetherin Abs.  Co-
immunoprecipitated proteins were analyzed by western blot using anti-Tetherin, anti-Vpu 
and anti-Env Abs.  The amount of proteins in the lysate prior to immunoprecipitation 
(input) is shown in the left panel. Non-specific bands, depicted by the asterisks, were 
used as loading controls. (B) Cell-surface expression of Tetherin. HeLa cells were 
transfected with the indicated HxBH10 proviral constructs and a GFP-expressing 
plasmid.  Cell-surface Tetherin expression was analyzed on GFP-positive cells by flow 
cytometry, 48h post-transfection.  MFI values are shown beside the histogram.  Filled 
histogram: pre-immune control; dashed line: HxBH10-vpu-; full line: HxBH10-vpu+; 
dotted line: HxBH10-vpu KSL. (C) Effect of Vpu on HIV-1 particle release. Cells and 
virus-containing supernatants were collected from the experiment described in (A), lysed 
and analyzed for the detection of Gag-related products by western blot using specific 
Abs. (D) Quantitation of virus particle release. Bands corresponding to Gag products in 
cells and virus particles were scanned by laser densitometry. The virus particle release 
efficiency was determined as described in the Materials and Methods and calculated as a 
percentage of the HxBH10-vpu+ virus release (100%). The error bars represent the 
standard deviation from the mean of three independent experiments. 
 
Figure 9:  Re-localization of Tetherin in the TGN requires the association of Vpu to 
the restriction factor. 
HeLa cells were infected with the indicated VSV-G pseudotyped HxBH10-derived virus.  
Forty-eight hours post-infection, cells were immunostained for cell-surface Tetherin, 
fixed, permeabilized and co-stained with anti-Tetherin (red), anti-Vpu (green) and anti-
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TGN46 (blue) specific Abs. Nuclei were counterstained with DAPI (cyan). Cells were 
observed by confocal microscopy. The white bar represents a distance of 10 µm.  
 
Figure 10. Model of Vpu-mediated down-regulation of Tetherin from the cell-
surface.  
In absence of Vpu, Tetherin traffics along the secretory pathway and reaches the plasma 
membrane. The protein is endocytosed, transported to the TGN and is then recycled back 
to the cell-surface. In presence of Vpu, Tetherin is forming complexes with the viral 
protein in the membrane of the ER. Recruitment of SCFβ-TrCP by Vpu leads to 
ubiquitination and proteosomal degradation of a fraction of Tetherin. Tetherin escaping 
degradation exits the ER. In the membrane of the TGN, Vpu binds endocytosed Tetherin 
and/or Tetherin arriving from the ER and causes the sequestration of the restriction 
factor. Subsequently, Vpu induces Tetherin ubiquitination through the recruitment of 
SCFβ-TrCP, targeting the ubiquitinated protein to lysosomal degradation. 
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SUPPORTING INFORMATION 
 
Figure S1 : Characterization of the Vpu S52D,S56D mutant.  
 (A) Association of Vpu with β-TrCP. HEK 293T cells were transfected with the 
indicated Vpu-expressing constructs and the myc-β-TrCP-encoding plasmid 
pcDNA/Myc-His-β-TrCP. Forty-eight hours post-transfection, cells were radio-labeled 
for 2h and lysed prior to sequential immunoprecipitation using anti-myc and, 
subsequently, anti-Vpu Abs. Co-immunoprecipitated proteins were separated by SDS-
PAGE and analyzed  by autoradiography. (B) Effect of Vpu S52D,S56D on Tetherin cell-
surface expression. HeLa cells were transfected with the indicated HxBH10 proviral 
constructs and a GFP-expressing plasmid.  Cell-surface Tetherin expression was analyzed 
on GFP-positive cells by flow cytometry, 48h post-transfection.  MFI values are shown 
beside the histogram.  Filled histogram: pre-immune control; dashed line: HxBH10-vpu-; 
full black line: HxBH10-vpu+; full grey line: HxBH10-vpu S52D,S56D. (C) Effect of 
Vpu S52D,S56D on HIV-1 particle release. HeLa cells were transfected with the 
indicated HxBH10 proviral constructs.  Cells and virus-containing supernatants were 
collected 48h post-transfection, lysed and analyzed for the detection of Gag-related 
products and Vpu by western blot using specific Abs. (D) Quantitation of virus particle 
release. Bands corresponding to Gag products in cells and virus particles were scanned by 
laser densitometry. The relative virus particle release efficiency was determined as 
described in the Materials and Methods and calculated as a percentage of the HxBH10-
vpu+ virus release (100%). The error bars represent the standard deviation from the mean 
of three independent experiments. 
Figure S2: Functional analysis of Tetherin chimeric proteins and the ∆GI,T45I 
mutant. 
(A) Design of Tetherin chimeric proteins and the human Tetherin ∆GI-T45I mutant. 
Cytoplasmic (Cyto), TM, coiled-coil and GPI domain as well as glycosylation and 
cleavage sites (dashed line) are represented. White: human Tetherin; grey: agm Tetherin.  
The amino-acid sequence of the mutant Tetherin ∆GI,T45I within the TM domain is 
shown below. Dots indicate deleted residues while hyphens indicate similar residues. (B-
E) HEK 293T cells were transfected with the specified HxBH10 proviral constructs and 
the indicated plasmids expressing (B) native or (D) HA-tagged Tetherin proteins.  Forty-
eight hours post-transfection, cells and virus-containing supernatants were harvested, 
lysed and proteins were analyzed by western blot using specific Abs. (C and E) 
Quantitation of B and D, respectively.  Bands corresponding to Gag products in cells and 
viral particles of panels B or D were scanned by laser densitometry. The virus particle 
release efficiency was determined as described in the Materials and Methods and 
calculated as a percentage of  the HxBH10-vpu+ release (100%) in absence of 
ectopically-expressed Tetherin. Error bars represent the standard deviation from the mean 
of two independent experiments. 
 
Figure S3: Functional analysis of Vpu mutants in HEK 293T cells.   
HEK 293T cells were transfected with plasmids encoding native Tetherin, the indicated 
HxBH10 proviral constructs and a GFP-expressing plasmid. (A) Forty-eight hours post-
transfection, cells and virus-containing supernatant were harvested, lysed and proteins 
were analyzed by western blot using specific Abs. (B) In parallel, cell-surface Tetherin 
expression was analyzed on GFP-positive cells by flow cytometry.  Geo mean values 
(depicted as MFI) are presented in the histograms.  Filled histogram: pre-immune control; 
dashed line: HxBH10-vpu-; full black line: HxBH10-vpu+; dotted line: HxBH10-vpu 
KSL; full grey line: HxBH10-vpu RD. 













